Sugi Predict

Sugi Predict / Compounds / SCHEMBL2156608

SCHEMBL2156608

SCHEMBL2156608

CCCCCC#C/C=C/S(=O)(=O)N1CCN(c2ccc(Cl)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ CNR1 P21554 1/20 0.42
▸ HSD11B1 P28845 1/20 0.40
▸ LSS P48449 1/20 0.39
▸ MAPT P10636 5/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ CETP P11597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2156613 1.00 GAA (0.46) GAAKDM4EMEN1KMT2ACNR1
SCHEMBL2155128 0.89 MEN1 (0.50) GAAMEN1KMT2ACNR1HSD11B1
SCHEMBL2156980 0.89 MEN1 (0.50) GAAMEN1KMT2ACNR1HSD11B1
SCHEMBL2155132 0.89 MEN1 (0.50) GAAMEN1KMT2ACNR1HSD11B1
SCHEMBL2155846 0.89 TSHR (0.51) GAAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL2155851 0.89 TSHR (0.51) GAAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL2154810 0.88 SMN1; SMN2 (0.54) KDM4EMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL2154808 0.88 SMN1; SMN2 (0.54) KDM4EMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL2156082 0.87 MAPT (0.54) GAAMEN1KMT2AHSD11B1MAPT
SCHEMBL2156078 0.87 MAPT (0.54) GAAMEN1KMT2AHSD11B1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 — — EP claimed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 — — US claimed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 — — US claimed
CN-101124213-A Sulfonylamino cyclic derivatives and uses thereof SERONO LAB (CH) 2008-02-13 — — CN claimed
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 — — EP disclosed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 — — US disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 — — US disclosed
CN-101124213-A Sulfonylamino cyclic derivatives and uses thereof SERONO LAB (CH) 2008-02-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof GLS2, SRM, GLS GAA 2816/4885KDM4E 1965/4885MEN1 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.